Ampersand Capital Partners

Ampersand Capital Partners is a Wellesley, Massachusetts-based middle-market private equity firm that invests exclusively in the healthcare and life sciences sectors. Its sub-vertical focus spans life sciences tools, diagnostics, and medical devices, which positions the firm closer to instrumentation, lab workflow, and physical product companies than pure software. The strategy is growth equity rather than control buyout, so Ampersand typically writes checks alongside founders and operators rather than executing full takeovers.

Check sizes fall in the $5M to $25M range, with deployment focused on US-based mid-market companies. Specific portfolio names in the healthcare AI segment are not provided in the source data.

For founders building AI tools embedded in lab instruments, diagnostics workflows, or medtech hardware, Ampersand is a relevant late-stage growth investor once the company has commercial revenue and a clear scaling plan. Pure software AI companies and early-stage startups should not target this firm. Approach when revenue is established, growth is funded, and the question is how to expand commercial reach rather than how to validate product.